Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Cash flows from operating activities
Net loss	$ (42,220)	$ (84,409)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation expense	674	533
Research and development license expense	3,500	1,250
Stock-based compensation	3,897	9,470
Non-cash lease expense	603	646
Other	387	387
Changes in operating assets and liabilities:
Prepaid expenses and other assets	509	80
Accounts payable	2,123	6,212
Accrued expenses and other liabilities	(1,324)	(8,461)
Deferred revenue	(7,101)
Net cash used in operating activities	(38,952)	(74,292)
Cash flows from investing activities
Purchase of research and development license		(3,250)
Purchase of property, plant and equipment	(3,852)	(16,290)
Net cash used in investing activities	(3,852)	(19,540)
Cash flows from financing activities
Net proceeds from issuance of common stock		11,640
Payment of shelf registration costs	(387)	(227)
Proceeds from common stock issuances under ESPP	50	321
Other	(156)	(766)
Net cash provided by financing activities	7	10,968
Net decrease in cash, cash equivalents and restricted cash	(42,797)	(82,864)
Cash, cash equivalents and restricted cash at the beginning of the period	90,517	151,740
Cash, cash equivalents and restricted cash at the end of the period	47,720	68,876
Cash and cash equivalents	45,083	66,239
Restricted cash	2,637	2,637
Supplemental disclosure of cash flow information:
Cash paid for interest	2,399	935
Supplemental disclosure of noncash investing and financing activities:
Property, plant and equipment in accounts payable and accrued expenses		2,722
Right-of-use assets obtained in exchange for lease liabilities		18,925
Offering costs not yet paid		109
Issuance of warrants in connection with private placement	252
Purchase of research and development license not yet paid	3,500	$ 1,000
Private Placement
Cash flows from financing activities
Net proceeds from issuance of common stock	$ 500